Price (delayed)
$2.05
Market cap
$50.58M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.66
Enterprise value
$44.81M
Rafael Holdings is focused on development of novel cancer therapies. The Company is a significant investor in two clinical stage oncology companies, Rafael Pharmaceuticals, Inc. and LipoMedix Pharmaceuticals Ltd. Through
There are no recent dividends present for RFL.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from and Sharadar.